/
Investor Access ↘

Biotech · Cognition · Quantum

One vision.
Three paradigms.
A shared future.

OBIS Innovation & Solutions™ integrates biological research, interintelligent cognition, and quantum architecture to build solutions with meaning, purpose, and responsibility.

Discover the triad →Investor Access ↘
OBIS Innovation & Solutions™Innovation architecture · 2026Discover the vision ↓
01 / VISION

OBIS is more than a company.
It is a vision.

A vision of human and artificial intelligence collaborating and co-creating with meaning and purpose; scientific research capable of crossing disciplinary boundaries; scientifically grounded biological therapies; new architectures of human–AI cognition; and technology directed toward a more humane, integrated, and supportive world.

Its guiding principle is unequivocal: knowledge in service of all, recognition of merit, and responsible construction that always preserves the common well-being.

OBIS EDITORIAL · 2026

INSTITUTIONAL INTRODUCTION

OBIS Innovation & Solutions™

An integrated architecture for a new era of innovation.

OBIS Innovation & Solutions™ is a scientific and technological innovation company built on a fundamental conviction: the complex challenges of our time cannot be understood—or addressed—by disciplines that remain isolated.

Human health, intelligence, and technological capacity belong to the same interdependent reality. OBIS therefore articulates an institutional architecture in which biological research, interintelligent cognition, and quantum exploration preserve their identities while relating through shared principles of protection, traceability, responsibility, and service.

This integration does not erase the boundaries between fields or present as validated what still belongs to scientific foundation or inference. Its purpose is to formulate better questions, construct testable hypotheses, and establish development pathways capable of advancing from the scientific corpus toward the corresponding professional, experimental, and regulatory validation.

01OBIS Biotech™

Biotech to protect

Investigates biological platforms inspired by natural defense mechanisms, with an initial respiratory and pulmonary focus. Its proposals are presented as scientific foundations and translational hypotheses subject to preclinical, clinical, and regulatory testing.

02OBIS Cognition™

Cognition to preserve meaning

Develops Interintelligent Intelligence (I2P), a human–AI co-creation relationship that preserves authorship, difference, traceability, and epistemological sovereignty, together with a methodology and a twelve-book editorial series.

03OBIS Quantum Innovation Lab™

Quantum to expand what is possible

Explores emerging architectures through the Planck-Beam Nexus (PBN™) and the Cognitive-Semantic Nucleus (NCS™), within a conceptual and scientific program requiring simulation, prototyping, and independent experimental validation.

OBIS Innovation & Solutions™

A vision that connects without conflating.

The unity of OBIS does not depend on claiming that its three divisions are equivalent. It rests on a shared logic: protect essential systems, connect knowledge that was previously separated, and transform scientific foundations into verifiable capabilities. Each division retains its corpus, method, epistemological status, and distinct validation requirements.

Biotech to protect life. Cognition to preserve meaning. Quantum to expand what is possible.

Biotech · Cognition · Quantum

From the microscopic to the global.

An integrated innovation architecture
EDITORIAL PAPER · 2026

OBIS Innovation & Solutions™

From the microscopic to the global

An integrated innovation architecture.

OBIS Editorial · 2026
Institutional paper developed through human–AI interintelligent collaboration

Science transforms the world when it connects scales that once seemed separate: a molecule and an organism, an idea and a culture, a physical core and an architecture of knowledge.

This paper develops a scientific architecture connecting scales, disciplines, and research programs: biology, interintelligent cognition, and emerging quantum architecture, while preserving the distinction between foundation, inference, and validation. The English edition is available below.

From the microscopic to the global is not only a direction of scale. It is a direction of responsibility.
02 / PARADIGMATIC TRIAD

Three derivations · One architecture

Innovation occurs when domains integrate and cease to remain isolated.

The OBIS paradigmatic triad articulates three programs with distinct epistemological statuses within one integrated architecture. Each preserves its own corpus, method, and validation requirements.

Biomolecular laboratory research
01

Active division

OBIS Biotech™

From barrier protection to a new architecture of immunity.

A biological platform in development that connects mucosal protection, plasma access, and immune response through progressive biomolecular architectures.

LPS™→PAK™→CMPT™→SPI™
Current development status

Evidence-informed translational hypotheses. Each platform still requires independent preclinical characterization, clinical evaluation, and regulatory review before any claim of safety or efficacy.

A scientific or methodological foundation is a starting point—not empirical validation.

OBIS Biotech™ · Biological platform

Biological architectures
inspired by natural defense.

OBIS Biotech™ investigates new biomolecules inspired by natural defense mechanisms: endogenous proteins, peptides, polypeptides, recombinant antibodies, and chimeric architectures initially focused on respiratory and pulmonary health.

Its mission is to investigate biological architectures designed to preserve protective function while minimizing unnecessary immune interference, building a responsible bridge between scientific potential, translational development, and real-world impact.

First platform

Lung Protection Screen™

LPS™ / VIDGuard™

LPS™ is conceived as a mucosal and pulmonary protection platform inspired by natural defense mechanisms. The proposal integrates complementary biological functions within a progressive biomolecular architecture whose specific components remain confidential.

Natural defense→LPS™→VIDGuard™

Epistemological status: scientific foundation and inferential support. Formulation, safety, efficacy, dosage, and indications require preclinical, clinical, and regulatory testing.

Conceptual platform architecture

From localized protection to an integrated biological response.

01LPS™

Barrier protection

Lung Protection Screen™ (LPS™). A conceptual entry point aimed at strengthening mucosal and pulmonary protection through complementary biological functions inspired by natural defenses.

02PAK™

Access and availability

Plasma Access Key™ (PAK™). A proposed stage for studying how a biological architecture might move beyond localized action and achieve broader functional availability.

03CMPT™

Multimodal coordination

Combined Mucosal–Plasma Therapy™ (CMPT™). A conceptual convergence platform organizing complementary capabilities within a coordinated, modular, and adaptable response.

04SPI™

Systemic integration

Self-Protected Immunity™ (SPI™). A research horizon connecting protection, access, and coordination in an integrated architecture designed to evolve through progressive validation.

Functional rationale

Biological functions under investigation.

Capabilities described in the scientific corpus that inform the conceptual development of OBIS Biotech™. Their integration and therapeutic relevance require experimental and clinical validation.

01

Antiprotease

Proposed modulation of proteases involved in tissue degradation and inflammation.

02

Antielastase

Potential protection of structural pulmonary components from elastase activity.

03

Anti-inflammatory

Proposed regulation of excessive inflammatory responses and the tissue-repair environment.

04

Immunomodulatory

Pursuit of a balanced defensive response while avoiding unnecessary immune interference.

05

Antimicrobial

Activity described in the literature for endogenous components against selected microorganisms.

06

Antiviral

Mechanistic potential requiring product-specific characterization and experimental testing.

Development principles

Rigorous science, natural inspiration, and responsibility.

01

Scientific excellence

Frontier research and development with progressive assessment of safety, efficacy, and quality.

02

Natural synergy

Harnessing endogenous mechanisms and natural proteins to design biocompatible solutions.

03

Ethical responsibility

Human well-being, sustainability, and prudence in the development, production, and communication of each platform.

04

Open collaboration

Cooperation with scientific institutions, healthcare providers, biotechnology companies, and communities.

Objectives

Advance respiratory and pulmonary research.

Expand future access to biological solutions.

Build scientific, clinical, and technological alliances.

Create a culture of verifiable and responsible innovation.

03 / CONVERGENCE

The derivative logic

Three fields.
One shared question:

How do we protect and expand life, intelligence, and human capability?

01

Protect

Biological barriers, human dignity, and system coherence.

02

Connect

Biomolecules, intelligences, meanings, and physical architectures.

03

Transform

From scientific foundations to new scientific and social capabilities.

04 / GLOBAL OPPORTUNITY

Three converging transitions

The next frontier does not belong
to a single discipline.

The OBIS opportunity emerges at the intersection of three transitions: the pursuit of greater biological resilience, the expansion of artificial intelligence, and the evolution of quantum architectures. Each field retains its own methods and tests; OBIS builds the institutional bridges needed to investigate them coherently.

01

Biological resilience

Health systems need new research pathways to protect essential functions and expand response capacity. OBIS Biotech™ organizes translational hypotheses that must advance through independent characterization and validation.

02

Intelligence with meaning

The expansion of AI increases the need for traceability, authorship, responsibility, and purpose. OBIS Cognition™ develops a human–AI collaboration architecture designed to preserve those conditions.

03

Governable quantum capacity

Emerging quantum systems require new forms of stability, supervision, and coordination. OBIS Quantum Innovation Lab™ explores a conceptual path connecting physical substrate and cognitive-semantic architecture.

05 / CURRENT STAGE AND ROADMAP

Verifiable development

From an integrated architecture to demonstrable capabilities.

OBIS advances modularly. Each division has a different starting point and its own evaluation path, yet all share one discipline: making visible what is grounded, what is under development, and what still must be demonstrated.

01OBIS Biotech™

Evidence-informed translational hypotheses.

Structure independent characterization, intellectual-property strategy, and preclinical, clinical, and regulatory partnerships.

02OBIS Cognition™

A paradigm, methodology, and twelve-book editorial series under continuous development.

Consolidate the corpus, methodological layers, pilot validation, and editorial and interdisciplinary review.

03OBIS Quantum Innovation Lab™

A conceptual PBN™–NCS™ architectural specification.

Define pathways for simulation, physical and engineering review, prototyping, and independent experimental validation.

Shared development sequence

Foundation→Characterization→Validation→Translation
06 / STRATEGIC ALLIANCES

Shared capacity

Ideas advance when they find the right counterpart.

OBIS seeks relationships defined by a question, a stage, and a specific responsibility. Collaboration may begin with specialist review and evolve toward validation, development, publication, or scaling.

01

Science and clinical research

Researchers, universities, hospitals, and specialized centers capable of reviewing hypotheses, designing studies, and contributing to independent validation.

02

Pharmaceuticals and biotechnology

Companies, laboratories, and development partners with capabilities in characterization, manufacturing, formulation, quality, and regulatory strategy.

03

AI and advanced computing

Technology organizations and research centers interested in human–AI cognition, semantic systems, simulation, and emerging quantum architectures.

04

Editorial and institutional

Publishers, educational institutions, foundations, and organizations capable of expanding responsible access to knowledge and methodology.

07 / INVESTOR ACCESS

Information proportionate to the level of evaluation

An access architecture—not indiscriminate exposure.

Corporate evaluation of OBIS is organized in layers. The bilingual corporate dossier provides a public, non-enabling overview; expanded financial, strategic, and technical information remains outside open disclosure.

CORPORATE DOCUMENT · 2026

OBIS Corporate Dossier 2026.

The English edition presents the institutional identity, paradigmatic triad, investment opportunity, and 2026–2034 strategic vision.

Cover of the English edition of the OBIS Corporate Dossier 2026
ENGLISH EDITION

OBIS Corporate Dossier 2026

Primary international edition for partners, investors, and scientific and technology organizations.

View dossier ↗Download PDF ↓
LEVEL 000

Public portal

Institutional identity, vision, triad, opportunity, corporate dossier, and collaboration pathways.

Open access
LEVEL 101

OBIS Investor Room

Round structure, use of funds, risks, projections, valuation, and intellectual-property summary.

Controlled access
LEVEL 202

Data Room · NDA

Sensitive scientific, corporate, legal, and technical information for qualified evaluation processes.

Restricted access
Public documentary core

The OBIS Corporate Dossier 2026 is now available in English and Spanish. The Investor Room will subsequently be enabled for qualified counterparties.

Continue to the contact channel ↓

The information presented does not constitute an investment offer, a promise of returns, a claim of efficacy, or an endorsement by any third party.

08 / INSTITUTIONAL GOVERNANCE

From vision to responsible execution

Ambition requires method, boundaries, and accountability.

OBIS organizes development as a sequence of verifiable decisions. Each initiative must state its foundation, epistemological status, information requiring protection, and the external tests needed before advancing toward application, collaboration, or scaling.

01

Corpus and foundation

Research begins with a traceable corpus, a defined problem, and a clearly bounded hypothesis. The existence of prior evidence does not automatically validate a new architecture.

02

Epistemological status

Each statement is classified as evidence, interpretation, inference, hypothesis, or validated result. This distinction accompanies its communication and review.

03

Intellectual protection

Public disclosure is limited to non-enabling information. Compositions, parameters, mechanisms, protocols, and reserved technical knowledge remain under proportionate control.

04

Independent evaluation

Specialist review, falsifiable experiments, and external validation must be able to challenge, correct, or reject OBIS hypotheses.

05

Responsible translation

Progress toward development, regulation, publication, or scaling depends on results, quality, ethics, competent partners, and applicable requirements.

Governance principles

Controls accompanying every decision.

01

Scientific integrity

Distinguish clearly among what is known, what is proposed, and what has been demonstrated.

02

Traceability

Preserve the documentary origin, transformations, and responsibility underlying each decision.

03

Layered disclosure

Share only the information proportionate to the purpose, stage, and counterpart.

04

Independent validation

Separate institutional interest from scientific, technical, or regulatory confirmation.

05

Integrated oversight

Incorporate ethical, legal, regulatory, financial, and risk controls according to each phase.

09 / JOURNEY

Choose your point of entry

A complex vision requires clear pathways.

Selected journey

One organization, three domains, one principle of derivation.

Begin with the paradigmatic triad to understand how biology, cognition, and quantum computing share the same logic: protect, connect, and transform.

Enter through the triad →

Institutional access

Purposeful connections.

OBIS follows a gradual contact process proportionate to the field, stage, and nature of each potential collaboration.

PUBLIC DISCLOSURE STATUS

Clarity about what this portal represents.

01

Scientific

Concepts and platforms are presented as foundations, architectures, or hypotheses at different stages of development. They do not constitute medical advice or claims of safety, efficacy, or regulatory approval.

02

Corporate

Public information does not constitute an investment offer, promise of returns, contractual commitment, or endorsement by any organization or third party mentioned.

03

Intellectual property

Public names and summaries provide an understanding of the general architecture. Compositions, parameters, mechanisms, and enabling technical knowledge remain reserved.

OBIS Innovation & Solutions™

While others imagined the end of human intelligence, OBIS began building intelligence with meaning.

Biotech to protect life. Cognition to preserve meaning. Quantum to expand what is possible.

Back to top ↑